Literature DB >> 23578675

Unruptured carotid artery aneurysms presenting with symptoms of mass effect: outcome after selective coiling, parent vessel occlusion, and flow diversion.

W J van Rooij1, M Sluzewski.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 23578675      PMCID: PMC7964670          DOI: 10.3174/ajnr.A3594

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


× No keyword cloud information.
  11 in total

1.  Flow-diverter silk stent for the treatment of intracranial aneurysms: 1-year follow-up in a multicenter study.

Authors:  J Berge; A Biondi; P Machi; H Brunel; L Pierot; J Gabrillargues; K Kadziolka; X Barreau; V Dousset; A Bonafé
Journal:  AJNR Am J Neuroradiol       Date:  2012-02-02       Impact factor: 3.825

2.  Early fatal hemorrhage after endovascular cerebral aneurysm treatment with a flow diverter (SILK-Stent): do we need to rethink our concepts?

Authors:  Bernd Turowski; Stephan Macht; Zolt Kulcsár; Daniel Hänggi; Walter Stummer
Journal:  Neuroradiology       Date:  2010-03-26       Impact factor: 2.804

3.  Partially thrombosed intracranial aneurysms presenting with mass effect: long-term clinical and imaging follow-up after endovascular treatment.

Authors:  S P Ferns; W J van Rooij; M Sluzewski; R van den Berg; C B L M Majoie
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

4.  Capitalism and commodities: my two cents.

Authors:  H J Cloft
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-14       Impact factor: 3.825

5.  Endovascular treatment of cavernous sinus aneurysms.

Authors:  W J van Rooij
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-27       Impact factor: 3.825

6.  Early and midterm results of complex cerebral aneurysms treated with Silk stent.

Authors:  Murat Velioglu; Osman Kizilkilic; Hakan Selcuk; Burak Kocak; Ercan Tureci; Civan Islak; Naci Kocer
Journal:  Neuroradiology       Date:  2012-06-14       Impact factor: 2.804

7.  Resolution of mass effect and compression symptoms following endoluminal flow diversion for the treatment of intracranial aneurysms.

Authors:  I Szikora; M Marosfoi; B Salomváry; Z Berentei; I Gubucz
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-14       Impact factor: 3.825

8.  Unruptured large and giant carotid artery aneurysms presenting with cranial nerve palsy: comparison of clinical recovery after selective aneurysm coiling and therapeutic carotid artery occlusion.

Authors:  W J van Rooij; M Sluzewski
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-22       Impact factor: 3.825

9.  Recovery of posterior communicating artery aneurysm-induced oculomotor palsy after coiling.

Authors:  M C J Hanse; M C F Gerrits; W J van Rooij; M P W A Houben; P C G Nijssen; M Sluzewski
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-13       Impact factor: 3.825

Review 10.  Endovascular treatment of large and giant aneurysms.

Authors:  W J van Rooij; M Sluzewski
Journal:  AJNR Am J Neuroradiol       Date:  2008-08-21       Impact factor: 3.825

View more
  3 in total

1.  Periprocedural safety of Pipeline therapy for unruptured cerebral aneurysms: Analysis of 279 Patients in a multihospital database.

Authors:  Robert J McDonald; Jennifer S McDonald; David F Kallmes; Giuseppe Lanzino; Harry J Cloft
Journal:  Interv Neuroradiol       Date:  2015-02       Impact factor: 1.610

2.  Parent artery occlusion in large, giant, or fusiform aneurysms of the carotid siphon: clinical and imaging results.

Authors:  M-A Labeyrie; S Lenck; D Bresson; J-P Desilles; A Bisdorff; J-P Saint-Maurice; E Houdart
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-31       Impact factor: 3.825

3.  Endovascular treatment of intracranial aneurysms in the flow diverter era: frequency of use and results in a consecutive series of 550 treatments in a single centre.

Authors:  Willem Jan van Rooij; Ratna S Bechan; Jo P Peluso; Menno Sluzewski
Journal:  Interv Neuroradiol       Date:  2014-08-28       Impact factor: 1.610

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.